Actavis Completes Acquisition of Auden Mckenzie


Actavis plc (NYSE: ACT) today announced that it has completed its acquisition of Auden Mckenzie Holdings Limited, a dynamic and fast growing company.




June 1, 2015

/PRNewswire/ --

Actavis plc

(NYSE: ACT) today announced that it has completed its acquisition of

Auden Mckenzie Holdings Limited

, a dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the UK.


acquired Auden Mckenzie for approximately £306 million in cash, plus a two-year royalty on a percentage of gross profits of one of Auden Mckenzie's products.



The acquisition of Auden Mckenzie makes


the number one supplier of generic pharmaceuticals in the


and gives the Company the number three position in the supply of



"The acquisition of Auden Mckenzie is a strategic combination that makes


the number one generic company in the


and aligns with our strategy to establish a leading position in all of our markets, franchises and therapeutic categories," said

Brent Saunders

, CEO and President of Actavis.

"Auden Mckenzie's expertise in the development and commercialization of high value, technically demanding formulations as well as specialized and niche opportunities is complementary to and expands



business focus," said

Robert Stewart

, Executive Vice President Actavis, and President, Generics and Global Operations. "The opportunity to combine this profitable and growing company into the Actavis UK business demonstrates our commitment to invest in and expand strategically in our global generics business."


currently markets more than 650 generic products in the


, and has approximately 85 additional products under registration and development. The combination with Auden Mckenzie adds approximately 175 new generic and branded products, as well as a pipeline of approximately 40 additional products, in various dosage forms, for treatments across a broad spectrum of therapeutic areas.

Related Videos
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Image credit: |
Medical team -- Image credit: Flamingo Images |
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin -
© 2024 MJH Life Sciences

All rights reserved.